Monoclonal antibodies against MADCAM1 and  are showing clinical benefits in inflammatory bowel disease [Sheridan, 2014], and hence based on our genetic results presented here, investigation of the effects of these drugs in T1D is worth considering. The gene discussed is MADCAM1; the disease is inflammatory bowel disease.